share_log

Apellis Pharmaceuticals | POSASR: Post-effective amendment to an automatic shelf registration statement on Form S-3ASR or Form F-3ASR

SEC ·  Feb 26, 2019 16:05
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more